TEL AVIV, Israel, July 05, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on
the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder
(ADHD) and Fragile X Syndrome (Fragile X), today announced that it will be presenting at the upcoming Cantor Fitzgerald
2nd Annual Healthcare Conference.
| Date: |
|
Tuesday, July 12 |
|
|
| Time: |
|
10:15am Eastern Daylight Time |
| Location: |
|
Le Parker Meridien, New York City |
About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of MDX, a proprietary
drug candidate, to treat cognitive disorders including ADHD and Fragile X. For more information please visit the Company's website,
www.alcobra-pharma.com, the content of which is not incorporated herein by
reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 mrice@lifesciadvisors.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 mikebeyer@sambrown.com Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 debbie@alcobra-pharma.com
